Feb. 21 2024—Binx Health announced it has entered into a national distribution agreement with Cardinal Health to expand access to care with its CLIA-waived, FDA-cleared Binx IO. The molecular point-of-care platform is used to detect chlamydia and gonorrhea in male and female patient samples and provides results in about 30 minutes.
“As we expand our commercial footprint, we’re very excited about this collaboration with Cardinal Health. Serving 90 percent of U.S. hospitals, 29,000 pharmacies, and 10,000 specialty physician office and clinics, their reach and brand are a leader in the industry,” Jeffrey Luber, CEO of Binx Health, said in a press statement.